

## **CINCLUS PHARMA'S NOMINATION COMMITTEE FOR THE 2025 ANNUAL GENERAL MEETING APPOINTED**

**According to the principles for the appointment of the Nomination Committee in Cinclus Pharma Holding AB (publ), adopted by the Annual General Meeting 2024, the Nomination Committee for the Annual General Meeting 2025 shall be composed of members appointed by the three largest shareholders as of September 30, 2024 along with the Chairman of the Board of Directors.**

The composition of the Nomination Committee has now been established, and the company today announces that the Nomination Committee for the 2025 Annual General Meeting consists of the following members:

Bitá Sehat, appointed by Trill Impact Ventures Pharma 1 AB

Karl Tobieson, appointed by Linc AB

Elin Häggbom, appointed by PetoMaj Invest AB

Lennart Hansson, Chairman of the Board, is an acting member of the Nomination Committee.

The shareholders who have appointed members to the Nomination Committee together represent approximately 17.4 percent of all shares in Cinclus Pharma Holding AB (publ) as of September 30, 2024.

Cinclus Pharma Holding AB (publ)'s Annual General Meeting will be held on Thursday May 22, 2025.

The Nomination Committee shall submit proposals for resolution by the 2025 General Meeting pertaining to the election of Chairman of the Meeting, fees and composition of the Board, auditors' fees and the election of auditors and, if necessary, proposal for changes in the instruction to the Nomination Committee. The Nomination Committee's proposals will be presented in the Notice to the Annual General Meeting 2025 and on Cinclus Pharma's website, [www.cincluspharma.com](http://www.cincluspharma.com).

Shareholders wishing to submit proposals to the Nomination Committee can do so by sending an e-mail to [corporate@cincluspharma.com](mailto:corporate@cincluspharma.com) (subject "Nomination Committee") or by letter posted to Cinclus Pharma Holding AB (publ), Attn: CFO Maria Engström, Kungsbron 1, SE-111 22, Stockholm, Sweden.

Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than February 28, 2025.

**For additional information, please contact:**

---

Christer Ahlberg, CEO  
Phone: +46 70 675 33 30  
e-mail: [christer.ahlberg@cincluspharma.com](mailto:christer.ahlberg@cincluspharma.com)

Charlotte Stjerngren, IR  
Phone: +46 70 876 87 87  
e-mail: [charlotte.stjerngren@cincluspharma.com](mailto:charlotte.stjerngren@cincluspharma.com)

**About Cinclus Pharma**

---

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit [www.cincluspharma.com](http://www.cincluspharma.com).

**Attachments**

---

**CINCLUS PHARMA'S NOMINATION COMMITTEE FOR THE 2025 ANNUAL GENERAL MEETING APPOINTED**